摘要
目的 评价 AFP、CA199、CA12 5联检对原发性肝癌中的诊治价值。方法 测定采用放射免疫分析法。结果 原发性肝癌患者血清 AFP的阳性率为 81.8% (2 7/33)、CA199阳性率为 6 3.6 % (2 1/33)、CA12 5的阳性率为 4 5 .5 % (15 /33)。肝血管瘤 AFP的均值为 (2 0 .4± 5 .4 ) ng/ml,原发性肝癌 AFP的均值为 (6 0 2 .5± 81.8) ng/ml,两组比较差异有非常显著性 (P<0 .0 1)。经手术后 AFP均值为 (30 .5± 9.2 ) ng/ml,与手术前的 AFP均值(6 0 2 .5± 81.8) ng/ml比较 ,差异有非常显著性 (P<0 .0 1)。结论 AFP、CA199、CA12 5联检有助于提高原发性肝癌的诊断符合率。
Objective To evaluate the value of combined detection of serum AFP?CA199 and CA125 for the diagnosis and therapy of primary liver cancer.Methods Measurements were carried out by radioimmunoassay.Results The positive rates of AFP?CA199 and CA125 were 81.8%(27/33)?63.6%(21/33) and 45.5%(15/33) respectively in prinary liver carcinoma.The average level of AFP was 20.4±5.4 ng/ml in angioma of liver and 602.5 ±81.8 ng/ml in malignant tumor( P <0.01).The average level of AFP dropped from 602.5 ±81.8 ng/ml before operation to 30.5±9.2 ng/ml postoperatively( P <0.01).Conclusion The combined detection of serum AFP?CA199 and CA125 could improve the diagnostic accuracy in primary liver cancer.AFP could also used for long time monitoring after surgery.
出处
《淮海医药》
2002年第4期281-282,共2页
Journal of Huaihai Medicine
